Profile data is unavailable for this security.
About the company
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
- Revenue in USD (TTM)247.00m
- Net income in USD-180.81m
- Incorporated1999
- Employees597.00
- LocationRevance Therapeutics Inc1222 Demonbreun Street, Suite 2000NASHVILLE 37203United StatesUSA
- Phone+1 (615) 724-7755
- Fax+1 (302) 655-5049
- Websitehttps://www.revance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inhibrx Biosciences Inc | 1.85m | 1.63bn | 234.65m | 166.00 | 0.1337 | 1.07 | 0.1434 | 126.63 | 121.21 | 121.21 | 0.0434 | 15.15 | 0.0079 | -- | 4.86 | 11,162.65 | 693.63 | -77.06 | 815.31 | -93.91 | -- | -- | 88,264.55 | -1,590.91 | -- | -21.96 | 0.00 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Lifecore Biomedical Inc | 128.45m | 5.71m | 248.21m | 524.00 | 182.46 | -- | 17.24 | 1.93 | 0.0369 | 0.0595 | 3.82 | 1.28 | 0.5217 | 2.01 | 4.96 | 245,124.00 | 2.32 | -5.91 | 2.74 | -8.33 | 34.65 | 31.01 | 4.45 | -19.16 | 0.803 | 0.125 | 0.7641 | -- | 24.20 | -25.46 | 114.53 | 34.47 | -16.72 | -- |
| Precigen Inc | 4.39m | -135.38m | 278.63m | 202.00 | -- | 5.71 | -- | 63.48 | -0.5407 | -0.5407 | 0.0176 | 0.1709 | 0.0313 | -- | 4.71 | 21,727.72 | -96.46 | -31.50 | -119.34 | -38.63 | -13.56 | 44.00 | -3,084.55 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Sanara Medtech Inc | 72.41m | -6.57m | 308.24m | 107.00 | -- | 7.39 | -- | 4.26 | -0.7788 | -0.7788 | 8.62 | 4.77 | 1.10 | 1.86 | 8.13 | 676,731.00 | -10.16 | -17.73 | -12.08 | -22.07 | 89.73 | 88.08 | -9.23 | -17.13 | 1.49 | -4.88 | 0.2577 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Biostem Technologies Inc | 131.44m | 7.87m | 371.35m | 67.00 | 68.14 | 20.51 | 45.94 | 2.83 | 0.3346 | 0.3346 | 7.31 | 1.11 | 2.80 | 7.41 | 3.35 | -- | 16.78 | -- | 107.11 | -- | 94.73 | -- | 5.98 | -- | 1.20 | 15.52 | 0.2012 | -- | -- | -- | -- | -- | -- | -- |
| Revance Therapeutics Inc | 247.00m | -180.81m | 385.47m | 597.00 | -- | -- | -- | 1.56 | -1.91 | -1.95 | 2.55 | -1.55 | 0.497 | 1.03 | 6.71 | 413,740.40 | -36.38 | -55.55 | -43.47 | -63.20 | 72.61 | -- | -73.20 | -304.96 | 3.05 | -15.40 | 1.58 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Rigel Pharmaceuticals Inc | 130.30m | -14.23m | 388.32m | 147.00 | -- | -- | -- | 2.98 | -0.8136 | -0.8136 | 7.45 | -1.70 | 1.06 | 1.05 | 5.24 | 886,401.40 | -11.59 | -28.82 | -19.93 | -47.26 | 92.41 | 97.88 | -10.92 | -35.76 | 1.48 | -1.73 | 2.00 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Theravance Biopharma Inc | 62.02m | -45.65m | 437.36m | 99.00 | -- | 2.26 | -- | 7.05 | -0.924 | -0.924 | 1.25 | 3.96 | 0.1534 | -- | 4.12 | 626,434.30 | -11.29 | -40.51 | -12.00 | -48.50 | -- | -- | -73.61 | -305.27 | -- | -- | 0.1305 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Esperion Therapeutics Inc | 295.45m | -86.77m | 447.39m | 240.00 | -- | -- | -- | 1.51 | -0.6585 | -0.6585 | 1.72 | -1.89 | 1.10 | 0.8275 | 5.35 | 1,231,046.00 | -32.41 | -69.45 | -74.85 | -101.81 | 81.58 | -- | -29.37 | -147.44 | 1.37 | 0.3253 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 298.76m | -165.87m | 456.15m | 384.00 | -- | 1.75 | -- | 1.53 | -2.45 | -2.45 | 4.34 | 3.84 | 0.7605 | 3.69 | 15.91 | 778,026.10 | -42.22 | -- | -50.91 | -- | 84.64 | -- | -55.52 | -- | 4.66 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Zevra Therapeutics Inc | 23.99m | -65.75m | 473.56m | 65.00 | -- | 11.64 | -- | 19.74 | -1.67 | -1.67 | 0.6106 | 0.7734 | 0.1919 | -- | 2.09 | 369,015.40 | -52.61 | -32.11 | -65.34 | -39.89 | 71.78 | -- | -274.10 | -128.42 | -- | -112.94 | 0.6423 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Aquestive Therapeutics Inc | 58.36m | -25.72m | 497.83m | 135.00 | -- | -- | -- | 8.53 | -0.3565 | -0.3565 | 0.7874 | -0.3896 | 0.6685 | 2.85 | 7.25 | 432,296.30 | -29.46 | -76.63 | -42.14 | -123.85 | 68.49 | 64.24 | -44.07 | -102.95 | 6.98 | -2.67 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Xeris Biopharma Holdings Inc | 181.41m | -59.56m | 517.03m | 377.00 | -- | -- | -- | 2.85 | -0.4215 | -0.4215 | 1.28 | -0.1295 | 0.5493 | 0.7428 | 4.99 | 481,201.60 | -18.04 | -43.60 | -23.57 | -56.57 | 83.72 | 78.23 | -32.83 | -143.08 | 1.69 | -1.59 | 1.09 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| SNDL Inc | 655.68m | -81.17m | 525.69m | 2.52k | -- | 0.5927 | -- | 0.8018 | -0.3107 | -0.3107 | 2.50 | 3.34 | 0.5988 | 4.63 | 33.15 | 260,604.80 | -7.67 | -24.44 | -8.32 | -27.94 | 25.04 | 22.49 | -12.82 | -62.17 | 2.98 | -- | 0.1125 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| SIGA Technologies Inc | 172.96m | 83.97m | 540.27m | 45.00 | 6.51 | 3.22 | 6.39 | 3.12 | 1.16 | 1.16 | 2.41 | 2.35 | 1.02 | 0.5866 | 23.09 | 3,843,484.00 | 49.52 | 22.34 | 56.21 | 27.56 | 82.00 | 88.65 | 48.55 | 41.14 | 5.65 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
Data as of Nov 08 2024. Currency figures normalised to Revance Therapeutics Inc's reporting currency: US Dollar USD
39.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 7.69m | 7.38% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 5.73m | 5.50% |
| Palo Alto Investors LPas of 30 Jun 2024 | 5.26m | 5.05% |
| Franklin Advisers, Inc.as of 30 Sep 2024 | 4.74m | 4.56% |
| Alpine Associates Management, Inc.as of 30 Sep 2024 | 4.16m | 4.00% |
| Polar Capital LLPas of 30 Jun 2024 | 3.57m | 3.42% |
| Stonepine Capital Management LLCas of 30 Jun 2024 | 2.80m | 2.69% |
| Rubric Capital Management LPas of 30 Jun 2024 | 2.66m | 2.55% |
| Geode Capital Management LLCas of 30 Jun 2024 | 2.30m | 2.21% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.28m | 2.19% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
